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factors and to reserve salvage radiotherapy for low-risk
patients, when biochemical recurrence occurs.
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Aim: To evaluate the prognostic role of prostatic apex tumor
invasion in patients undergoing radical prostatectomy for
prostate cancer (pca) clinically organ-confined, and to define
its correlation with clinical and pathologic variables (age,
clinical stage, preoperative psa,% frustules positive biopsy,
Gleason score, surgical margin status). Patients and
Methods: From our database of 1693 patients who
underwent rp between 2000 and 2012 for clinically
localized pca, data from 498 patients with pathological stage
t2 were retrospectively evaluated. The entire prostate was
examined with 2-4 mm intervals transections in a plane
perpendicular to the urethra. The apical prostate was
separately sectioned and examined in parallel slices and
“apical involvement” was defined as the presence of
neoplastic glands in the last 8 mm of the prostate. Patients
with lymph nodes involvement were treated with early
adjuvant hormonal therapy. Biochemical relapse was defined
as the evidence of psa>0.2 ng/ml in two consecutive
measurements. The probability of biochemical recurrence
was estimated by the Kaplan-Meier method, with the log-
rank test used to evaluate differences among levels of the
analyzed variables (apical involvement, preoperative psa,
gleason score, pathological stage, surgical margins status).
The multivariate Cox proportional hazard model was used
to estimate the relative importance of the variables in
predicting survival. Results: Overall 280 patients (56.2%)
had neoplastic involvement of the prostatic apex. The mean
follow-up was 40 months (range 6-154). In 30 patients
(6.02%) a biochemical relapse was observed, with a mean
time of 30 months (range 3-149). Positive surgical margins
were observed in 34 patients (6.8%), of whom, 26 (76.4%)
presented involvement of the prostatic apex. The number
and the percentage over the total of neoplastic biopsy cores
were predictor factors of tumor apex involvement
(p=0.018). The biochemical recurrence-free survival (brfs)
for patients with positive apex was lower than in patients
with negative apex (91.9% vs. 95.9% at 36 months, 88 %
vs. 92.8 % at 60 months and 86% vs. 92.8% at 120 months,
respectively) (p=0.05). Positive surgical margins, the apex
involvement and pathological stage were significantly
correlated with biochemical relapse at univariate analysis.
Multivariate analysis confirmed the statistical independence
of positive surgical margins (p=0.0004, rr=5.17) and apex
involvement (p=0.0536, rr=2.47). Conclusion: The prostatic
apex represents a crucial anatomical structure during radical
prostatectomy for both oncological and functional outcomes.
The absence of a well anatomically defined capsule at this
level suppose the risk of understaging at final pathological
analysis. Our data showed that tumor invasion into the
prostatic apex is a significant prognostic factor regardless of
the status of surgical margins.
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Aim: We tested a selected series of patients with single
urothelial high-grade pT1 stage (pT1 HG) or urothelial
carcinoma in situ (CIS) with a set of immunohistochemical
markers to elaborate a risk score for progression. Patients and
Methods: We retrospectively reviewed all first diagnoses of
single, <3 cm, urothelial papillary carcinoma pT1 HG or
isolated CIS between 2006 and 2009. Galectin-3, CD44, E-
cadherin, CD138, p16, survivin, HYAL-1, and topoisomerase-
II α were used. A grading score 0 or 1 for each
immunohistochemical staining was assigned to obtain a total
score for assessing progression. The median “progression
score” was selected as cut-off value for statistical analysis.
Overall, 23 patients (19 pT1 HG and 4 CIS) were included in
the study. Results: After a median follow-up of 21 months
(range, 12 to 34 mo), 9 patients (39.1%) showed disease
recurrence whereas 4 patients (17.4%) showed tumor
progression. Topoisomerase-II α, p16, survivin, galectin-3,
and CD138 were significantly associated with progression.
Progression score ranged from 0 (best prognosis) to 7 (worst
prognosis). Using a score ≥5 as a threshold, specificity was
78.9%, sensitivity 100%, positive predictive value 50%, and
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negative predictive value 100%. ROC area (a 95% confidence
interval, 0.807-1.000; p<0.001). Conclusion: This
immunohistochemistry-based progression score using a
threshold ≥5, might help the clinician to focus on patients
with HG pT1 or extended CIS at high risk for disease
progression. These patients might benefit from a more
intensive follow-up program or early cystectomy.
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Aim: To evaluate the characteristics of long term biochemical
relapse in a cohort of patients undergoing radical
prostatectomy for clinically localized prostatic disease with
pathologic stage t2. Patients and Methods: From our database
of 1628 patients who underwent radical prostatectomy from
2000 to 2012 we analyzed data from 727 patients, mean age
65.1 aa (range, 43-78 yr), with organ-confined disease at the
definitive histopathological examination. Biochemical relapse
of disease was defined as the relief of psa>0.2 ng/ml in two
consecutive samples. Survival was assessed using the Kaplan-
Meyer method with the log rank test for univariate analysis
and the Cox method for multivariate analysis. We analyzed:
the characteristics of biochemical relapse, the need and
response to treatment and clinical and pathologic variables
which correlate most with the relapse. Results: Surgical
margins were positive in 64/727 patients (8.8%) and negative
in 663/727 (91.2%). Nerve sparing technique (bilateral or
unilateral) was performed in 480 of the 727 patients. The
mean follow-up was 34.6 months (range 6-154). A
biochemical relapse of disease was observed in 73/727
patients (10.04%). The mean time of relapse was 23.9 months
(median 23.5, range 3-149). Of these 73 patients, 34
underwent delayed treatment (19 hormonal therapy, 15
radiotherapy). The opportunity of a treatment was evaluated
according to patient age, comorbidities and time of relapse.
Thirty-nine patients (53.4%) presented an elevation of psa
>0.2 ng/ml, which remains stable in a range between 0.2 and
0.5 ng/ml over the years without any radio or hormonal
therapy. The disease-free survival was significantly higher for
patients with negative margins (p<0.0001). Pathological stage
(pt2a, pt2b pt2c) and the presence of positive surgical margins
(both p<0.0001) significantly correlate with the biochemical
relapse, and were both confirmed as predictor factors at the
multivariate analysis (p=0.04 and <0.001, respectively).
Conclusion: An important rate of patients (>50%) presented
a stable value of psa between 0.2 and 0.5 ng/ml over the years
without any additional therapy. These data show that radical
prostatectomy provides control of the disease in almost all
patients with organ-confined disease, and, despite the
occurrence of biochemical relapse, a treatment is not always
necessary.
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Introduction: Morphological CTM detection in voided urine
samples is a cheap and universally adopted exam, though
affected by a relatively low sensitivity, because of the usual
challenge represented by the interpretation of the “atypical”
category. Hence, new analytical methods of cancer detection
like abnormal level of NMP22 matrix protein obtained a lot of
attention in the last decade. NMP22 is an enzyme linked
immunoassay performed in fresh collected urine, aimed to
identify the NuMA matrix protein of the neoplastic urothelial
cells. The exam is a time (30’ to get the answer) and cost
effective approach to the problem of splitting the wide
“atypical” category of urine sediment. Methods: We analyzed
43 fresh voided urine samples both for cytology (one sediment
as opposed to the conventional 3 days/3 sediment approach)
and NMP22 of 43 patients submitted to TURB resection in the
following hours (same day). Results: 36 out of 43 patients were
positive for papillary urothelial carcinoma (18 low grade and
18 high grade), while 7 cases were affected by cystic cystitis.
19/36 (overall sensitivity: 52%) positive cases were CTM+
(4/18 low grade and 15/18 high grade); 8/36 cases were
NMP22+ (overall sensitivity: 22%): 4/18 low grade and 4/18
high grade. None of the 7 negative cases showed
morphological or NMP22 positivity. 15/19 cases of CTM+
cases were NMP 22 negative. 4/8 cases of NMP22+ cases were
CTM negative (low grade papillary carcinoma). Comments: In
the present experience, NMP22 is a test affected by a low
sensitivity. Nevertheless, in combination with cytology it may
increase the sensitivity of tumor detection, particularly in low
grade tumors. Nevertheless, a limitation of our comparison
between the two methods is due to the single sediment analysis
of the CTM morphological investigation method, that might
have further affected its sensitivity (52%).
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